NEW YORK (GenomeWeb News) – RNAi research services company Definiens said today that Cenix BioScience has expanded a license agreement to continue to use Definiens’ data extraction technology in its microscopy assays for high throughput RNAi studies in human and rodent cells.
 
Under the agreement, Cenix will integrate the Definiens Cellenger system into its existing high-throughput and high-content RNAi-based research infrastructure, the company said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.